Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

- PMLiVE

Novo Nordisk growth takes a hit with China deal

Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products

- PMLiVE

Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn

The pharma company has been collaborating with Dicerna on its RNAi gene silencing platform since 2019

- PMLiVE

Novo Nordisk settles US insulin pricing dispute for $100m

Novo Nordisk admits no liability or wrongdoing but will pay investors $100m to “avoid the burden, inherent risk and expense of further litigation”

- PMLiVE

Eli Lilly to acquire Protomer Technologies in a deal worth over $1bn

Protomer Technologies is a US biotech company focused on engineering glucose-responsive insulin

- PMLiVE

Novo Nordisk signs deal for Prothena’s heart drug worth up to $1.2bn

Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy

- PMLiVE

Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

Ozempic 2 mg demonstrated a 2.2% reduction in blood sugar compared with a 1.9% reduction for those receiving Ozempic 1 mg

- PMLiVE

Novo Nordisk partners with Heartseed on heart failure cell therapy

Heartseed is eligible to receive up to a total $598m as part of the collaboration and licence agreement

Improving Public Health Through Telemedicine

Laurence Girard, CEO of Fruit Street Health, shares his tips for aspiring HealthTech entrepreneurs, his views on the future of telemedicine and digital health, and why he thinks healthcare companies...

Impetus Digital

- PMLiVE

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019

- PMLiVE

Lilly partners with Biolojic Design to develop diabetes antibody therapies

Agreement could be worth up to $121m in milestone payments

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

- PMLiVE

Novo Nordisk launches late-stage study in Alzheimer’s disease

Study will evaluate oral semaglutide in neurodegenerative disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links